Xintela AB
Research Xintela AB (XINT) on Bullrun: market cap SEK 145.55M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerXINT
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 145.55M
- Financial periodQ1 2026
- RevenueSEK 443.00K
- Net income-SEK 11.78M
- Free cash flow-SEK 12.93M
- Gross margin100.0%
Valuation Snapshot
latest market cap is SEK 145.55M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 2.28M | -SEK 48.56M | -SEK 41.69M | 100.0% | -0.07 | SEK 23.21M | n/a | -SEK 5.27M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-28 | SEK 145.55M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Xintela AB
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome; and EQSTEM that is in preclinical development for the treatment of joint disease in horses.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Xintela AB's market cap?
Xintela AB's market capitalization is SEK 145.55M.
What does Xintela AB do?
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome; and EQSTEM that is in preclinical development for the treatment of joint disease in horses.